Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2013, Article ID 269569, 6 pages
http://dx.doi.org/10.1155/2013/269569
Research Article

In Vivo Efficacy of HD0471953: A Novel GPR119 Agonist for the Treatment of Type 2 Diabetes Mellitus

1Hyundai Pharmaceutical Co. Ltd., 204-4 Nonhyeon 1-dong, Gangnam-gu, Seoul 135-545, Republic of Korea
2College of Veterinary Medicine, Chonnam National University, Gwangju 500-757, Seoul 135-545, Republic of Korea

Received 25 June 2013; Revised 2 October 2013; Accepted 2 October 2013

Academic Editor: Raffaele Marfella

Copyright © 2013 So Ra Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. A. DeFronzo, R. C. Bonadonna, and E. Ferrannini, “Pathogenesis of NIDDM: a balanced overview,” Diabetes Care, vol. 15, no. 3, pp. 318–368, 1992. View at Google Scholar · View at Scopus
  2. S. I. Taylor, D. Accili, and Y. Imai, “Insulin resistance or insulin deficiency: which is the primary cause of NIDDM?” Diabetes, vol. 43, no. 6, pp. 735–740, 1994. View at Google Scholar · View at Scopus
  3. J. Meece, “Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies,” Current Medical Research and Opinion, vol. 23, no. 4, pp. 933–944, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Ho, A. K. C. Leung, and D. Rabi, “Hypoglycemic agents in the management of type 2 diabetes mellitus,” Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, vol. 5, no. 1, pp. 66–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. Ross and J.-M. Ekoé, “Incretin agents in type 2 diabetes,” Canadian Family Physician, vol. 56, no. 7, pp. 639–648, 2010. View at Google Scholar · View at Scopus
  6. Z.-L. Chu, R. M. Jones, H. He et al., “A role for β-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release,” Endocrinology, vol. 148, no. 6, pp. 2601–2609, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. R. M. Jones, J. N. Leonard, D. J. Buzard, and J. Lehmann, “GPR119 agonists for the treatment of type 2 diabetes,” Expert Opinion on Therapeutic Patents, vol. 19, no. 10, pp. 1339–1359, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Barnett, “DPP-4 inhibitors and their potential role in the management of type 2 diabetes,” International Journal of Clinical Practice, vol. 60, no. 11, pp. 1454–1470, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. H. A. Overton, M. C. T. Fyfe, and C. Reynet, “GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity,” British Journal of Pharmacology, vol. 153, supplement 1, pp. S76–S81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. R. Burge, V. Sood, T. A. Sobhy, A. G. Rassam, and D. S. Schade, “Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review,” Diabetes, Obesity and Metabolism, vol. 1, no. 4, pp. 199–206, 1999. View at Google Scholar · View at Scopus
  11. S. A. Amiel, T. Dixon, R. Mann, and K. Jameson, “Hypoglycaemia in type 2 diabetes,” Diabetic Medicine, vol. 25, no. 3, pp. 245–254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. W. H. W. Tang, “Do thiazolidinediones cause heart failure? A critical review,” Cleveland Clinic Journal of Medicine, vol. 73, no. 4, pp. 390–397, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Creutzfeldt and R. Ebert, “New developments in the incretin concept,” Diabetologia, vol. 28, no. 8, pp. 565–573, 1985. View at Google Scholar · View at Scopus
  14. J. L. Iltz, D. E. Baker, S. M. Setter, and R. Keith Campbell, “Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus,” Clinical Therapeutics, vol. 28, no. 5, pp. 652–665, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Barnett, J. Allsworth, K. Jameson, and R. Mann, “A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies,” Current Medical Research and Opinion, vol. 23, no. 7, pp. 1493–1507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Raun, P. von Voss, C. F. Gotfredsen, V. Golozoubova, B. Rolin, and L. B. Knudsen, “Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not,” Diabetes, vol. 56, no. 1, pp. 8–15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Bekur, M. V. Nagaraja, K. N. Shivashankara, and W. Stanley, “Sitagliptin-induced hemolysis,” Indian Journal of Pharmacology, vol. 42, no. 5, pp. 320–321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. N. Iyer, A. J. Drake III, R. L. West, C. E. Mendez, and R. J. Tanenberg, “Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide,” Endocrine Practice, vol. 18, no. 1, pp. e10–e13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Yokota and N. Igaki, “Sitagliptin (dpp-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report,” Journal of Internal Medicine, vol. 51, no. 15, pp. 2041–2044, 2012. View at Google Scholar
  20. D. J. Drucker, T. Jin, S. L. Asa, T. A. Young, and P. L. Brubaker, “Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line,” Molecular Endocrinology, vol. 8, no. 12, pp. 1646–1655, 1994. View at Google Scholar · View at Scopus
  21. Z.-L. Chu, R. M. Jones, H. He et al., “A role for β-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release,” Endocrinology, vol. 148, no. 6, pp. 2601–2609, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Giorgino, A. Leonardini, A. Natalicchio, and L. Laviola, “Multifactorial intervention in type 2 diabetes: the promise of incretin-based therapies,” Journal of Endocrinological Investigation, vol. 34, no. 1, pp. 69–77, 2011. View at Publisher · View at Google Scholar · View at Scopus